MaxCyte Inc (MXCT) Ord USD0.01 (DI)
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
MaxCyte upgrades revenue guidance after operational review
9 December 2024 08:55
(Sharecast News) - Cell engineering technology specialist MaxCyte announced upgraded revenue guidance on Monday, following an operational review under its new chief executive officer Maher Masoud.
-
MaxCyte appoints new chief commercial officer
10 October 2024 13:23
(Sharecast News) - Cell engineering company MaxCyte announced the appointment of Ali Soleymannezhad as its new chief commercial officer on Thursday, effective from 11 September.
-
MaxCyte enters licence agreement with Kamau Therapeutics
16 September 2024 11:22
(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence agreement with Kamau Therapeutics, a clinical-stage firm specialising in stem cell gene correction...
-
MaxCyte reports solid second-quarter performance
7 August 2024 12:36
(Sharecast News) - Cell engineering company MaxCyte reported a robust financial performance for its second quarter on Wednesday, with total revenue reaching $10.4m, a 15% increase compared to the same period...
-
MaxCyte reports strong first quarter
8 May 2024 12:45
(Sharecast News) - MaxCyte reported total first-quarter revenue of $11.3m in an update on Wednesday, making for a 32% increase compared to the same period in 2023.
-
MaxCyte reports strong fourth quarter as full-year revenues fall
13 March 2024 12:04
(Sharecast News) - Cell engineering technology specialist MaxCyte reported total fourth quarter revenue of $15.7m on Wednesday, up 26% on the same period in 2022.
-
MaxCyte flags lower 2023 revenue, flat 2024 growth
5 March 2024 13:01
(Sharecast News) - Cell engineering technology specialist MaxCyte said in an update on Tuesday that it expected total 2023 revenue of between $41.1m and $41.3m, down from $44.3m in 2022.
-
MaxCyte flags uptick in total fourth-quarter revenue
9 January 2024 08:55
(Sharecast News) - Cell engineering company MaxCyte said on Tuesday that total fourth-quarter revenue was expected to be between $15.5m and $15.7m.
-
Maher Masoud starts as MaxCyte president, CEO
2 January 2024 11:25
(Sharecast News) - MaxCyte confirmed the appointment of Maher Masoud as its new president and chief executive officer on Tuesday, effective from 1 January.
-
MaxCyte announces new CEO, updates revenue guidance
12 December 2023 13:46
(Sharecast News) - Cell engineering technology specialist MaxCyte announced a significant chief executive transition on Tuesday and updated its revenue guidance for 2023.
-
MaxCyte joins Alliance for mRNA Medicines
16 November 2023 13:57
(Sharecast News) - Cell engineering company MaxCyte announced its membership in the Alliance for mRNA Medicines (AMM) as a founding member on Thursday.
-
MaxCyte lowers full-year guidance after weaker third quarter
5 October 2023 13:00
(Sharecast News) - Cell engineering specialist MaxCyte revised its full-year guidance downwards on Thursday based on its preliminary third-quarter revenue.
Company announcements Announcements
-
Holding(s) in Company
19 December 2024 16:26
Maxcyte (DI)
-
Holding(s) in Company
18 December 2024 15:31
Maxcyte (DI)
-
Holding(s) in Company
10 December 2024 17:16
Maxcyte (DI)
-
Holding(s) in Company
10 December 2024 17:12
Maxcyte (DI)
-
MaxCyte Streamlines Operations and Raises Guidance
9 December 2024 07:00
Maxcyte (DI)
-
Total Voting Rights and Block Listing Return
2 December 2024 17:09
Maxcyte (DI)
-
Holding(s) in Company
28 November 2024 15:05
Maxcyte (DI)
-
Holding(s) in Company
28 November 2024 15:05
Maxcyte (DI)
-
Holding(s) in Company
19 November 2024 09:49
Maxcyte (DI)
-
Filing of 10Q form
7 November 2024 07:00
Maxcyte (DI)
-
Third Quarter 2024 Financial Results
7 November 2024 07:00
Maxcyte (DI)
-
Exercise of options and PDMR dealing
6 November 2024 13:43
Maxcyte (DI)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.